×
About 1,183 results

ALLMedicine™ Lipoprotein (a) Center

Research & Reviews  581 results

Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein c...
https://doi.org/10.1093/eurheartj/ehab218
European Heart Journal; Imamoto K, Kataoka Y et. al.

Apr 6th, 2021 - Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging.|2021|Im...

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emergin...
https://doi.org/10.1093/cvr/cvab100
Cardiovascular Research; Swerdlow DI, Rider DA et. al.

Mar 26th, 2021 - Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein (a) Lp(a)]-targeting therapy has yet been...

Coronary calcification is associated with elevated serum lipoprotein (a) levels in asym...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939167
Medicine Chung YH, Lee BK et. al.

Mar 3rd, 2021 - Lipoprotein a (Lp (a)) and coronary artery calcification (CAC) are markers of coronary artery and cardiovascular diseases. However, the association between Lp (a) and CAC in asymptomatic individuals remains unclear. In this study, we aimed to dete...

Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and ...
https://doi.org/10.1093/eurjpc/zwaa063
European Journal of Preventive Cardiology; Welsh P, Welsh C et. al.

Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...

The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a)...
https://doi.org/10.1177/2047487320905727
European Journal of Preventive Cardiology; Dal Pino B, Bigazzi F et. al.

Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|

see more →

Clinicaltrials.gov  593 results

Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein c...
https://doi.org/10.1093/eurheartj/ehab218
European Heart Journal; Imamoto K, Kataoka Y et. al.

Apr 6th, 2021 - Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging.|2021|Im...

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emergin...
https://doi.org/10.1093/cvr/cvab100
Cardiovascular Research; Swerdlow DI, Rider DA et. al.

Mar 26th, 2021 - Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein (a) Lp(a)]-targeting therapy has yet been...

Coronary calcification is associated with elevated serum lipoprotein (a) levels in asym...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939167
Medicine Chung YH, Lee BK et. al.

Mar 3rd, 2021 - Lipoprotein a (Lp (a)) and coronary artery calcification (CAC) are markers of coronary artery and cardiovascular diseases. However, the association between Lp (a) and CAC in asymptomatic individuals remains unclear. In this study, we aimed to dete...

Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and ...
https://doi.org/10.1093/eurjpc/zwaa063
European Journal of Preventive Cardiology; Welsh P, Welsh C et. al.

Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...

The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a)...
https://doi.org/10.1177/2047487320905727
European Journal of Preventive Cardiology; Dal Pino B, Bigazzi F et. al.

Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|

see more →

News  9 results

Novartis aims to pump up cardio business with Ionis deal
https://www.reuters.com/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT

Feb 25th, 2019 - ZURICH (Reuters) - Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto. FILE ...

Niacin's effect on cardiovascular risk: Have we finally learned our lesson?
https://www.mdedge.com/ccjm/article/96071/cardiology/niacins-effect-cardiovascular-risk-have-we-finally-learned-our-lesson?channel=194
Stephen J. Nicholls, MBBS, PhD

May 1st, 2014 - Randomized controlled trials have unequivocally shown that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of cardiovascular events. 1–3 Yet many patients still have heart attacks even though they are on.

Lp(a) Gene Variant Associated With Aortic Stenosis
https://www.medscape.com/viewarticle/778878

Feb 5th, 2013 - MONTREAL, Quebec — An international consortium has identified a variation in the gene coding for lipoprotein (a) (Lp[a]), which appears to be strongly associated with aortic-valve calcification [1]. People carrying this single nucleotide polymorph...

Lp(a) Does Predict Risk in Blacks, New ARIC Data Show
https://www.medscape.com/viewarticle/754584

Nov 30th, 2011 - December 1, 2011 (Houston, Texas) — Elevated levels of lipoprotein (a) [Lp(a)] are associated with cardiovascular events in African Americans, and the risk is comparable to that seen in whites, a new analysis of the Atherosclerosis Risk in Communi...

Lp(a) Is a Causal Factor for CVD, But a Modest One
https://www.medscape.com/viewarticle/706265

Jul 20th, 2009 - July 21, 2009 (Cambridge, United Kingdom) — A new pooled analysis of 36 prospective studies shows there is a continuous association between blood concentration of lipoprotein (a)--Lp(a)--and the risk of MI and stroke [1]. Importantly, this associa...

see more →